179 related articles for article (PubMed ID: 33093336)
1. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
Jungels C; Karfis I
Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
[TBL] [Abstract][Full Text] [Related]
2. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
[TBL] [Abstract][Full Text] [Related]
3. High-specific-activity
Dillon JS; Bushnell D; Laux DE
Future Oncol; 2021 Apr; 17(10):1131-1141. PubMed ID: 33506713
[TBL] [Abstract][Full Text] [Related]
4. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Pandit-Taskar N; Chen CC
Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501
[TBL] [Abstract][Full Text] [Related]
5. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
6. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
7. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.
Jimenez C; Núñez R; Wendt R
Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):162-169. PubMed ID: 32250976
[TBL] [Abstract][Full Text] [Related]
8. Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas.
Araujo-Castro M; Pascual-Corrales E; Alonso-Gordoa T; Molina-Cerrillo J; Martínez Lorca A
Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):614-628. PubMed ID: 36402734
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
[TBL] [Abstract][Full Text] [Related]
10. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
11. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of [
Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K
Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465
[TBL] [Abstract][Full Text] [Related]
13. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990
[TBL] [Abstract][Full Text] [Related]
15. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial for [
Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983
[TBL] [Abstract][Full Text] [Related]
17. Radiopharmaceutical treatment of pheochromocytomas.
Sisson JC
Ann N Y Acad Sci; 2002 Sep; 970():54-60. PubMed ID: 12381541
[TBL] [Abstract][Full Text] [Related]
18. 131I-MIBG--a new agent in diagnosis and treatment of pheochromocytoma.
Shapiro B; Sisson JC; Eyre P; Copp JE; Dmuchowski C; Beierwaltes WH
Cardiology; 1985; 72 Suppl 1():137-42. PubMed ID: 4053121
[TBL] [Abstract][Full Text] [Related]
19. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
[TBL] [Abstract][Full Text] [Related]
20. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
